… Dapagliflozin has been shown to reduce the risk of cardiovascular death, hospitalization
for heart failure or … and preserved ejection fraction, which provides strong support for the …

… was prompt and maintained throughout the study, with a reduction in HbA1c … reduced
hospitalization for heart failure and death.25 The ongoing Dapagliflozin Effect on CardiovascuLAR …

… In Asian populations, the risk of T2D and cardiovascular disease is elevated at a lower body
… lead-in period during which they were maintained on open-label metformin at their pre-…

… patients with heart failure. This article reviews the benefits of Dapagliflozin to patients with
heart failure. … ejection fraction, HFrEF),保留型心衰(heart failure with preserved ejection fraction, …

: 非奈利酮是一种新型非甾体醛固酮受体拮抗剂, 其心肾保护作用已得到证实. 钠-葡萄糖共转运
蛋白-2 抑制剂是一类新型降糖药. 近期研究表明, 其具有独立于降糖的心血管及肾脏保护作用. 两…

… This update mainly covers chronic heart failure including heart failure with mildly reduced …
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction[J]. N Engl J Med…

… cardiovascular events. At present, the value of SGLT2 inhibitors in the treatment of heart failure
with reduced … a certain therapeutic value in heart failure with preserved ejection fraction (…

… patients with moderate to severe renal insufficiency, the research progress of these patients
is … This article reviews the current research status of CKD with heart failure, with a view to …

… 在没有CKD 的情况下,射血分数保 留的心力衰竭(heart failure with preserved ejection fraction,
HFpEF)患者1 年,5 年,总体和长期… Dapagliflozin in patients with heart failure … reduced ejection …

… effect could be further extended to heart failure mildly reduced ejection fraction(HFmrEF)…
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale …